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Do CD1-Restricted T Cells Contribute to Antibody-Mediated
Immunity against Mycobacterium tuberculosis?
Mark L. Lang1* and Aharona Glatman-Freedman2
Department of Microbiology and Immunology, Dartmouth Medical School, Lebanon, New Hampshire 03756,1
and Department of Pediatrics, Children’s Hospital at Montefiore, Albert Einstein College
of Medicine, Bronx, New York 104612
More than 100 years after the discovery of the tubercle
bacillus by Robert Koch (43) and approximately 50 years after
the introduction of effective antimycobacterial therapeutic
agents (3, 4, 46), tuberculosis (TB) continues to be a leading
cause of morbidity and mortality worldwide (18, 81). The ba-
cillus Calmette-Guérin (BCG) vaccine, in use since the 1920s,
protects young children against disseminated TB, but it does
not prevent the development of pulmonary TB, which is the
most prevalent and contagious form of the disease (2). In
recent years many efforts have focused on the identification of
new vaccine candidates against Mycobacterium tuberculosis.
These vaccine candidates include live attenuated, DNA, and
subunit vaccines (reviewed in reference 16). However, the
BCG vaccine and most vaccine candidates against TB are
thought to protect the host by augmenting cell-mediated im-
munity to control mycobacterial replication after the infection
has already been established. This mechanism of protection
differs substantially from that of most vaccines currently used
in humans against many pathogens. Such vaccines confer pro-
tection by eliciting protective antibody (Ab) responses, which
in turn are thought to eliminate the infecting inoculum (61).
For many decades, the scientific paradigm was that Ab plays
little or no role in the host defense against M. tuberculosis.
Several factors played a role in forming this paradigm: the
theory that the immune response to a particular microorgan-
ism was either cell mediated or Ab mediated, the view that host
defense against intracellular microorganisms was primarily a
function of cell-mediated immunity, and the belief that intra-
cellular pathogens were not accessible to Abs. In addition,
great difficulty was encountered by investigators trying to dem-
onstrate natural protective Ab responses to M. tuberculosis
(reviewed in references 27 and 28). However, in recent years,
studies from several laboratories used monoclonal Abs
(MAbs) to demonstrate beneficial effects of Abs on various
aspects of M. tuberculosis infection (11, 17, 30, 57, 76, 80).
ANTIBODIES TO GLYCOLIPIDS, LIPOGLYCANS, AND
POLYSACCHARIDES CAN MODIFY THE OUTCOME OF
MYCOBACTERIUM TUBERCULOSIS INFECTION
Some important examples of the role of Abs against M.
tuberculosis include the experience with Abs to lipid- and po-
lysaccharide-containing mycobacterial fractions. Costello and
colleagues found that children with disseminated TB had lower
immunoglobulin G (IgG) titers to the lipoglycan lipoarabino-
mannan (LAM) than controls (19). They also measured IgG
Ab titers to mycobacterial antigens (Ags) in children from the
United Kingdom who were not immunized with BCG and not
infected with M. tuberculosis. They found that maternally trans-
mitted IgG to mycobacterial antigens declined to a nadir at
around 3 months of age and remained low until 2 years of age.
The Ab levels then gradually increased, reflecting the subject’s
own production of Ab to mycobacterial antigens. Abs to LAM
were particularly low during the 3-month to 2-year period, with
little or no LAM-specific IgG detected (19). Interestingly, the
peak incidence of disseminated tuberculosis occurs between
the ages of 6 months and 2 years, when levels of antibody to
LAM are minimal (19).
Khuller and colleagues demonstrated that the M. tuberculo-
sis glycolipid phosphatidylinositol mannoside (PIM) could in-
duce protective Ab responses in mice immunized with lipo-
some-encapsulated or bovine serum albumin-conjugated
vaccines (53, 71). Immunization with PIM decreased the bac-
terial burden in the lungs and prolonged survival. Passive im-
munization with sera from vaccinated mice also conferred pro-
tection in naive hosts challenged with live M. tuberculosis.
Seibert and colleagues tested Ab responses in rabbits after
BCG immunization. They found that rabbits with resistance to
TB produced high Ab titers to both mycobacterial proteins and
polysaccharides, while rabbits that were susceptible to TB de-
veloped mostly protein-specific Abs, suggesting that polysac-
charide-specific Abs confer protection (68). In a second study
by the same group, production of antimycobacterial polysac-
charide Ab following immunization with BCG and mycobac-
terial protein was inversely correlated with disease severity and
survival time after challenge with a virulent strain of M. tuber-
culosis (69). The authors concluded that the production of Abs
to mycobacterial polysaccharides in addition to antiprotein
Abs was important for enhanced animal survival after exposure
to M. tuberculosis (67). The investigators further hypothesized
that free mycobacterial polysaccharide not encountered by Ab
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interfered with a protective immune response against M. tu-
berculosis (69).
Abs specific for lipid antigens may also play a role in host
defense against M. tuberculosis. Trehalose 6,6-dimycolate
(cord factor)-specific Abs induced by immunization with cord
factor complexed with methylated bovine serum albumin neu-
tralized the toxic effects of mycolic acid, as manifested by
prolonged survival and maintenance of body weight in mice
receiving cord factor intraperitoneally (38).
The studies described above were performed with serum,
which contains polyclonal antibodies. Recent studies with
MAbs provide additional examples for the role of glycolipid-,
lipoglycan-, and polysaccharide-specific Abs in host defense
against M. tuberculosis. MAb 9d8, an IgG3 Ab directed to
arabinomannan (AM), was demonstrated to prolong the sur-
vival of mice infected with a lethal dose of M. tuberculosis. Mice
that received the M. tuberculosis Erdman strain coated with
MAb 9d8 survived significantly longer than controls (76). Pro-
longed survival was seen in several mouse strains, including
gamma interferon- and major histocompatibility complex
(MHC) class II-deficient mice. The improved survival was as-
sociated with changes in the histological response to M. tuber-
culosis infection in the lungs of mice that were consistent with
an enhanced granulomatous response (76).
Another study aimed to determine the effect of Ab on free
mycobacterial polysaccharide, a concept that was originally
introduced by Seibert and colleagues (68). In that study, the
effect of MAb 5c11, a LAM-binding MAb, on the clearance
and organ distribution of mannose-capped LAM (ManLAM)
was examined in mice (30). In the absence of MAb 5c11,
intravenously administered ManLAM was taken up by margin-
al-zone macrophages (M) of the spleen and, to a lesser de-
gree, by the liver. MAb 5c11 administered before the injection
of ManLAM enhanced the clearance of ManLAM from the
circulation and affected its organ distribution (30). In the pres-
ence of MAb 5c11, ManLAM was shunted towards the hepa-
tobiliary system, where bile and bile salts caused a reduction in
its immunoreactivity (30). Another study recently demon-
strated that the LAM-binding MAb SMITHB14 prolonged
survival, prevented weight loss, and reduced CFU in mice
infected with M. tuberculosis when administered before or con-
currently with mycobacterial challenge (31). It therefore ap-
pears that Abs reactive with glycolipid-, lipoglycan-, and po-
lysaccharide-containing structures can confer protection
against M. tuberculosis.
GLYCOLIPIDS AND LIPOGLYCANS ARE POTENT
VIRULENCE FACTORS
It is not known why Abs reactive to glycolipids, lipoglycans,
and polysaccharides confer protection, but this could be re-
lated to findings that these molecules are potent virulence
factors providing M. tuberculosis with several survival advan-
tages. Ab-mediated neutralization of the effects of virulence
factors could “swing the balance” in favor of the host. M.
tuberculosis sheds cell wall glycolipid molecules, including
LAM and its biosynthetic precursor PIM (7, 63), as well as the
polysaccharide AM (29). LAM and PIM are major contribu-
tors to M. tuberculosis evasion and subversion of the host im-
mune response (21, 37, 70, 78, 79). Several effects of LAM on
the immune system have been described (13, 37, 59, 65, 70),
but of great interest is the discovery that LAM inhibits func-
tional maturation of the M. tuberculosis-containing M phago-
some (Fig. 1) (21, 78). Phagosome maturation is characterized
by the signaling-regulated sequential delivery of endocytic ves-
icle cargo to the phagosome. The vesicle cargo includes a wide
array of innate microbicidal agents, including proteolytic en-
zymes, and MHC class II, a trigger of adaptive immune re-
sponses (12, 26, 35). In contrast to LAM, PIM increases trans-
port of early endosomes but not late endosomes or lysosomes
to the M. tuberculosis phagosome (79). Early-endosome trans-
port to phagosomes allows delivery of transferrin receptors,
bearing transferrin/iron complexes (14, 79). Iron is critical for
M. tuberculosis survival (reviewed in reference 15).
Thus, M. tuberculosis cell wall glycolipids are potent viru-
lence factors that operate by enhancing nutrient delivery to the
M phagosome or contributing to evasion or subversion of
M-mediated innate and adaptive immune responses. Abs to
LAM and PIM, for instance, could potentially interfere with
inhibition of innate M killing mechanisms and the initiation
of adaptive immunity (Fig. 1). Little is known about how Abs
confer protection against M. tuberculosis. Hamasur and col-
leagues demonstrated recently that F(ab)2 fragments of anti-
LAM Abs were equally protective to whole Ab, supporting a
neutralization-based mechanism rather than Fc receptor-me-
diated effector functions for certain Abs (31). Therefore, it is
essential that investigators determine the mechanism(s) by
which Abs reactive with such virulence factors protect the host.
CD1-RESTRICTED T CELLS PROVIDE HELP FOR
ANTIBODY PRODUCTION
CD1 represents a family of nonpolymorphic MHC class I
molecules that present lipid-associated carbohydrate struc-
tures to CD1-restricted T cells (8, 58). Humans express five
known CD1 isoforms (CD1a to -e) (8, 58). Mice express a
single CD1 isoform that is highly homologous to human CD1d
(58). The M. tuberculosis virulence factors LAM and PIM are
glycolipid antigens that bind CD1b and CD1d, leading to ac-
tivation of CD1b-restricted  Th cells and CD1d-restricted
natural killer-like T (NKT) cells, respectively (20, 59). Other
M. tuberculosis Ags, such as mycolic acid, also stimulate CD1b-
restricted T cells (55). Of note, several galactosylceramide
molecules from diverse bacterial species have been identified
as CD1d Ags (39, 52), suggesting that observations related to
M. tuberculosis Ags may be relevant to other bacterial species.
Expression of the single CD1d isoform in mice has resulted
in more extensive study of the role of CD1d-restricted NKT
cells in producing Abs reactive to CD1-binding Ags. The in-
formation obtained from such studies may guide research on
CD1b- and CD1c-restricted T cells in Ab responses. All pro-
fessional antigen-presenting cells (APCs), including B cells,
present CD1d Ags (23, 24, 64, 72, 74). NKT cells stimulated by
-galactosylceramide (-GalCer) produce interleukin-4 (IL-4),
consistent with creating a cytokine environment necessary for
Ab production (6, 9, 75). Kitamura and colleagues showed that
-GalCer stimulated NKT cells to activate B cells in vivo,
resulting in increased expression of MHC class II, B7.2, and
the activation marker CD69 (40). The effects of NKT cells on
B cells were also shown to be IL-4 dependent (40). Thus far,
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published findings are consistent with CD1d/Ag expressed on
B cells stimulating NKT cells to create a cytokine environment
that in turn will activate B cells and promote Ab production.
Several laboratories have reported that NKT cells can pro-
vide help for Ab production in a CD1d-dependent manner (10,
25, 48, 66). The M. tuberculosis-derived CD1d-binding Ag PIM
activates NKT cells (20), but it is not known whether a PIM-
specific B-cell antigen receptor (BCR) can capture PIM to
facilitate CD1d presentation to NKT cells and result in Ab
production. PIM induces Ab production in the absence of a
protein carrier, suggesting but not proving MHC class II-inde-
pendent Ab production (71). Support for CD1-mediated Ab
production is provided by the recent finding that production of
Abs reactive with polysaccharide Ags from Streptococcus pneu-
moniae is CD1d dependent (42). In the S. pneumoniae study,
CD1/ mice immunized with pneumococcal polysaccharide
Ags failed to elicit an IgG response (42). Importantly, this
suggests that polysaccharide-derived Ag may also bind CD1d
and activate NKT cells. These findings are very important to
this discussion because they indicate that protective Abs spe-
cific for polysaccharides could also be produced in a CD1-
dependent manner.
In a separate study, CD1/ mice infected with the spiro-
chete Borrelia hermsii demonstrated impaired production of
specific Ab and had a higher pathogen burden than CD1d-
expressing controls (5, 44). Schofield and colleagues showed
that the glycosylphosphatidylinositol (GPI) moiety on the Plas-
modium berghei-derived malarial circumsporozoite protein was
required for production of Ab reactive to the protein compo-
nent and that the response was abrogated in CD1/ mice
(66). This finding demonstrates that presentation of a CD1d-
binding component (GPI) of a GPI-linked protein can stimu-
late help from CD1d-restricted T cells for production of pro-
tein-specific Ab, even though peptides derived from the
protein are presented on MHC class II.
Galli and colleagues showed that human peripheral B cells
cocultured with autologous NKT cells produced IgG in re-
sponse to stimulation with -GalCer (25). This suggests that
human CD1d-restricted NKT cells contribute to Ab produc-
tion. Campos et al. showed that production of IgM by B-1 B
cells mediating contact sensitivity reactions was dependent on
CD1d expression (10). Two separate studies also showed that
sensitization of mice via subcutaneous OVA immunization,
followed by intranasal OVA administration, induced airway
hypersensitivity, eosinophilia, and anti-OVA IgE production in
a CD1d/NKT-dependent manner (1, 48). Importantly, in both
of these studies IgE production was not entirely dependent on
CD1d-restricted T cells. This indicates that MHC class II- and
CD1d-restricted T cells might both contribute to the Ab re-
sponse, a finding that has been supported by studies showing
that CD1d/ and MHC class II/ mice produce IgE, albeit
at lower levels than in wild-type mice (82). Recently, -GalCer
was shown to have potential as an adjuvant that could be
administered intranasally to induce protein Ag-specific IgA
(41). This could have consequences for inducing antibody-
mediated immunity to M. tuberculosis at mucosal surfaces.
Our recent research has addressed the mechanism for pro-
duction of Abs reactive with CD1-binding Ags (45). We dem-
onstrated in vitro that if CD1-binding glycolipid (-GalCer)
was targeted to the BCR (within anti-BCR Ab complexes), it
resulted in a 100-fold-enhanced activation of CD1d-restricted
NKT cells compared to nontargeted Ag. In the same study, we
FIG. 1. M. tuberculosis-derived glycolipids promote survival in the host M and evasion of the host immune response. M. tuberculosis (MTB)
resident in the host M phagosome sheds PIM and LAM to exert effects on intracellular vesicle trafficking. LAM prevents trafficking of late
endosomes (LE) to the phagosome, thus inhibiting delivery of Ag presentation machinery and inhibiting the adaptive immune response (21, 22).
Although not directly proven, evasion of innate immune responses might be similarly mediated, via inhibition of primary and secondary granule
trafficking. PIM enhances delivery of early and recycling endosomes (EE) to the phagosome and is suggested to increase levels of essential nutrients
in the phagosome, thus contributing to M. tuberculosis survival (79). Tf, transferrin.
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demonstrated that the BCR facilitated enhanced uptake of
LAM or -GalCer to CD1d-containing organelles and that
colocalization of Ag with CD1d was essential for NKT activa-
tion. These findings support the hypothesis that CD1 Ag-spe-
cific BCR could capture Ag to facilitate intracellular acquisi-
tion by CD1d and subsequent presentation to NKT cells and in
turn stimulate help for Ab production in vivo.
A substantial number of publications support the concept
that CD1d-restricted T cells provide help for Ab production,
but a few controversies remain. For example, in contrast to the
findings of Schofield and colleagues (66), Procopio and col-
leagues showed that production of Abs reactive to GPI-an-
chored mucins of Trypanosoma cruzi was not CD1d dependent
(60). This suggests that not all carbohydrate structures are
presented by CD1d. Additionally, Molano and colleagues re-
ported that production of Ab reactive to the GPI-linked cir-
cumsporozoite protein was not CD1 mediated (54). Differ-
ences in genetic background arising via different numbers of
backcrosses of the CD1/ mice may provide some explana-
tion for the different results, but notably, when the Ab re-
sponse was CD1d independent, a larger amount of irradiated
sporozoites than in the experiments of Schofield et al. was used
to infect the mice. Interestingly Schofield et al. reported that 1
ng of native GPI-anchored protein induced an Ab response
comparable to that with 10 g of recombinant (non-GPI
linked) protein (66). In other words, CD1d-restricted T cells
provided help in response to very small amounts of Ag. This
suggests that the disparity in results between the two studies
could have been caused by high Ag levels overcoming the
requirement for CD1d-restricted T cells and stimulating MHC
class II-restricted T cells to produce Ab. These studies suggest
that CD1d- and MHC class II-restricted T cells may be oper-
ating at two different levels of sensitivity. Therefore, CD1d-
restricted NKT cells may be capable of enhancing Ab production
in response to very low levels of Ag early in infection.
One other area of interest pertaining to Ab production me-
diated by CD1-restricted T cells is the B-cell compartment(s)
involved in such responses. Investigators have proposed that
splenic marginal zone (MZ) B cells may produce Abs in a
CD1-dependent manner. Murine MZ B cells express high lev-
els of CD1 and produce Abs reactive to carbohydrate epitopes
(reviewed in references 50 and 51). Direct evidence has been
obtained by Belperron and colleagues, who demonstrated that
MZ B cells produced Abs reactive with Borrelia hermsii carbo-
hydrate Ags in a CD1d-dependent manner (5). This suggests
the potential for MZ B-cell-dependent production of Abs re-
active with M. tuberculosis-derived glycolipid, lipoglycan, or
polysaccharide Ags.
A PROPOSED MECHANISM FOR CD1-MEDIATED
ANTIBODY PRODUCTION
The evidence presented here supports the concept that
CD1d-restricted T cells can provide help for Ab production in
vivo. A model for this concept is shown in Fig. 2. We propose
that the BCR specificity and Ag structure (and thus CD1-
binding moieties) will influence the relative contribution of
CD1-restricted T cells to Ab production. Vaccination with
pure protein or CD1-binding Ags may skew the response to-
wards MHC class II-restricted or CD1-restricted T cells, re-
spectively (Fig. 2). A more likely scenario (during infection or
following vaccination with carbohydrate-lipid-protein conju-
gates) is that due to uptake of antigenic complexes containing
glycolipid and protein or polysaccharide and protein, MHC
class II- and CD1-restricted T cells will provide help for Ab
production. The BCR may be specific for a peptide or carbo-
hydrate epitope (or a combination of both) and could capture
protein, carbohydrate (including CD1-binding glycolipids/lipo-
glycans), or a structure consisting of all these moieties (either
covalently bound or associated). Ag processing will then result
in the generation of MHC class II-binding peptides as well as
CD1-binding glycolipids/lipoglycans. Presentation on both
MHC class II and CD1 will in turn elicit help from MHC class
II- and CD1-restricted T cells. The relative contributions of
MHC class II- and CD1-restricted T cells may also depend on
the relative levels of MHC class II and CD1 Ag presentation.
As shown in the model, other CD1-expressing professional
APCs, particularly dendritic cells (DCs) and perhaps macro-
phages, will likely influence or even be required for the induc-
tion of CD1-mediated Ab responses. CD1 Ags such as -GalCer
(CD1d) and LAM (CD1b) are captured and presented by
dendritic cells and M (23). However, the exact effect (if any)
of DCs and on CD1-dependent Ab production is at present
unknown. DCs rather than B cells prime naive MHC class
II-restricted Th cells to provide help for Ab production in vivo
(36, 62). Whether B cells, DCs, or both prime CD1-restricted
T cells and affect priming of MHC class II-restricted Th cells is
not established. Furthermore, Ags with distinct structures may
skew the in vivo Th1/Th2 balance via activation of APCs and
lead to distinct immunological outcomes (cell-mediated versus
humoral immunity) (56, 83). The contribution of other APCs
to the Ab response may therefore be governed at least in part
by the specific Ag.
IS THERE POTENTIAL FOR A NOVEL VACCINE
STRATEGY AGAINST TB?
The polysaccharide vaccines are among the most successful
to be used in recent years, and they include vaccines against
Haemophilus influenzae type b, Streptococcus pneumoniae, Sal-
monella enterica serovar Typhi, and meningococcal serogroup
C (49, 77). These are protein-conjugated polysaccharide vac-
cines that elicit effective T-cell-dependent Ab responses. The
Salmonella enterica serovar Typhi conjugate vaccine serves as
an example of a vaccine that provides protection against a
facultative intracellular pathogen by eliciting a protective Ab
response (47). To date, several polysaccharide conjugate vac-
cine candidates have been described, among them LAM-de-
rived oligosaccharide conjugated to tetanus toxoid, cross-reac-
tive mutant (CRM197) diphtheria toxoid (33), or antigen 85B
or a 75-kDa protein of M. tuberculosis (32). A vaccine candi-
date consisting of AM conjugated to recombinant Pseudomo-
nas aeruginosa exoprotein A has also been developed (29).
These vaccines were immunogenic and elicited IgG re-
sponses in immunized animals (29, 32). Vaccine candidates
consisting of LAM-derived oligosaccharides conjugated to pro-
tein carriers prolonged survival and prevented weight loss in
mice and guinea pigs infected with a virulent strain of M.
tuberculosis (32). We demonstrated that immunization of mice
with AM-recombinant P. aeruginosa exoprotein A conjugate
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vaccine resulted in a CFU reduction 7 days after infection with
M. tuberculosis Erdman strain or Mycobacterium bovis BCG. It
is worth highlighting that the effect on CFU was noted early
after infection, prior to the development of effective cell-me-
diated immunity (29). As mentioned, PIM-containing lipo-
somes or PIM-bovine serum albumin conjugates have been
used as vaccines to stimulate Ab-mediated protection in mice
challenged with M. tuberculosis (53, 71). These results provide
a strong basis for continued investigation of polysaccharide-
and glycolipid/lipoglycan-derived vaccines and new investiga-
tions into the mechanism(s) of protective Ab production.
Since it is possible that not all M. tuberculosis Ags induce
protective Ab responses, the Ag (or mixture of Ags) chosen for
vaccination is likely to be critical. In this regard, the difficulties
encountered with the development of meningococcal polysac-
charide vaccines (34, 73), especially to serogroup B (34), and
the encouraging breakthrough made in recent years with the
serogroup C meningococcal vaccine (73) highlight the impor-
tance of choosing a suitable Ag(s) for vaccine development.
We hypothesize that there are several criteria that an Ag
should fulfill to be useful as a vaccine component to enhance
Ab-mediated protection against M. tuberculosis. The Ag should
be critical to the growth and survival of M. tuberculosis and
accessible to Ab. The Ag should be presented on MHC class II
and/or CD1 to a T-cell receptor whereby the affinity of inter-
action stimulates an appropriate “T helper” response that fa-
vors Ab production. The CD1-restricted T cell should contrib-
ute to isotype switch and somatic hypermutation (at the
immunoglobulin locus), thus generating Ab with sufficiently
high affinity to confer protection against challenge with live M.
tuberculosis. Additionally, the vaccine should trigger suffi-
ciently long-term immunity, ideally stimulating lifelong protec-
tion. At present, we do not know what the relative contribu-
tions of CD1-restricted T cells to these intricate processes are.
Careful experimentation using well defined CD1-binding Ags
will be necessary to achieving the goal of understanding the
contribution of CD1-restricted T cells to Ab production and
how to stimulate protective Ab responses.
FIG. 2. Increased help for Ab production mediated by CD1-restricted Th or NKT cells. In this model, we propose the following. (i) DCs capture
protein, glycolipids, or complexes and subsequently present Ag in the context of CD1d to CD1d-NKT cells or present MHC class II to MHC class
II-restricted Th cells. DCs therefore prime NKT and Th cells for further activation by Ag-presenting B cells. (ii) B cells capture Ag via a specific
BCR to facilitate presentation to DC-primed NKT and/or Th cells. (iii) The T cell is stimulated via cognate interactions to produce IL-4 and to
increase receptor engagement between the T cell and the B cell. (iv) The cytokine environment combined with receptor-mediated help stimulates
Ab production. In this model, the relative contribution of MHC class II- and CD1-restricted help may depend on the relative affinity of glycolipid
and peptide Ag for the T-cell receptor (TCR). Whether CD1- and MHC class II-restricted T cells interact directly to affect Ab production is not
known.
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CONCLUDING REMARKS
Based on the studies reported thus far with MAbs specific
for mycobacterial CD1-binding antigens, it appears that Abs
can have beneficial effects on the course of M. tuberculosis
infection if present at the time of host-pathogen engagement.
Thus, we believe that Ab-inducing vaccine candidates should
be developed with the intention of preventing infection rather
than controlling M. tuberculosis replication after infection has
already been established. The variables that are important for
the successful development of such vaccines need to be exten-
sively evaluated. Learning how to appropriately stimulate
CD1-restricted T-cell responses may be critical in the success-
ful development of such vaccines.
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